Translational research builds upon years of basic scientific knowledge to discover truly revolutionary novel therapies and treatments. While long an impressively innovative field, its astronomical growth in recent years has led to a acceleration of the discovery and diagnostic timeline. This panel will discuss recent advances in translational research as they relate to the “bench-to-bedside” collaborative approach to bringing scientific innovation to patients.
garret a. fitzgerald, MD, FRS
Director, Penn Institute for Translational Medicine and Therapeutics
Dr. Garret FitzGerald directs the Institute for Translational Medicine and Therapeutics. His work contributed fundamentally to the development of low-dose aspirin for cardioprotection. FitzGerald’s group was the first to predict and then mechanistically explain the cardiovascular hazard from NSAIDs. He has also discovered many products oflipid peroxidation and established their utility as indices of oxidant stress in vivo. His laboratory was the first to discover a molecular clock in the cardiovascular system and has studied the importance of peripheral clocks in the regulation of cardiovascular and metabolic function. He is a member of the National Academy of Medicine, The Accademia dei Lyncei, an honorary member of the Royal Irish Academy, a Fellow of the American Academy of the Arts and Sciences and of the Royal Society. He is a Senior Advisor to Calico Laboratories.
Garret A. FitzGerald, MD, FRS, Professor of Medicine and Pharmacology, McNeil Professor in Translational Medicine and Therapeutics, Director, Institute for Translational Medicine & Therapeutics, Perelman School of Medicine, University of Pennsylvania, USA
joseph camardo, md, fcpp
Senior Vice President, Celgene Global Health
Joseph Camardo completed his BA at the University of Pennsylvania, followed by a year in neuroscience research and a three-month sojourn to study Indian music in Benares. He earned an MD from University of Pennsylvania School of Medicine in 1979. Dr. Camardo has worked in basic neuroscience research at Columbia University and was a Dana Fellow at the University of Pennsylvania, during which time he also practiced general medicine in Philadelphia. In 1989 he joined the Clinical Research division of Wyeth-Ayerst Laboratories; as this company grew in size and scope Dr. Camardo took positions with additional responsibility as head of Clinical Research and head of Medical Affairs at Wyeth. He is now Senior Vice President at Celgene Corporation, Head of Global Health and a member of Corporate Affairs. Dr. Camardo is chair of the Board of MaliHealth, an NGO that works with mothers and children in Bamako, Mali; he is a Fellow of the College of Physicians of Philadelphia, a member of the Institute for Ethical Leadership and Social Responsibility at Rosemont College, and board member of Anyone Can Fly, an arts foundation in NYC. He continues to play piano as one of the founding musicians of a band called The Jazz Doctors.
venkat sethuraman, MD
President, Spine Physician’s Institute
Dr. Venkat Sethuraman MD, MBA is an Orthopaedic Spine Surgeon actively practicing in the Dallas, Texas. He completed his residency at Thomas Jefferson University Hospital and his fellowship at the Mayo Clinic. He is nationally recognized as a specialist in minimally invasive spine and revision spine surgery. As a surgical pioneer, entrepreneur, and innovator he graduated from the Executive MBA program at the Wharton School of Business in 2017. His interests include healthcare management and value based medicine that will lead to changes that drive more cost containment and transparency in health care, while still improving autonomy for healthcare providers.
steven nichtberger, md
Co-Founder, Chairman & Chief Executive Officer, Cabaletta Bio
Dr. Nichtberger has more than 25 years of healthcare industry experience, developing, commercializing and investing in breakthrough medical advances. He is co-founder, chairman, and CEO of Cabaletta Bio, which is developing cellular therapies for B cell-mediated autoimmune diseases. As managing partner of GBF, LLC, he provided investing and advisory services to healthcare companies, investors, and leading academic scientists to maximize the value of breakthrough advances. He held senior roles at ControlRad, Tengion, Limelight Bio, and Merck & Co. As adjunct professor at Wharton, he leads the Life Sciences & Management capstone course on healthcare company formation, financing, and leadership.
The Wharton School MBA Candidate
Chris Ragsdale is currently pursuing an MBA in health care management at The Wharton School, where he is the recipient of the Henry J. Kaiser Family Foundation Scholarship in recognition of professional achievements in health care. Prior to Wharton, Chris was a consultant in the public sector advisory practice of PwC, where he provided management consulting services to the Centers for Medicare and Medicaid Services (CMS) and other federal and state agencies. His work with CMS focused on the implementation of value-based payment models under the Affordable Care Act and the prevention of fraud, waste, and abuse in Medicare. Chris has also worked at UnitedHealth Group and St. Vincent’s Healthcare, an Ascension hospital system in Jacksonville, Florida. Chris received his B.S. in Environmental Studies and Medical Humanities from Davidson College, where he also served as student body president.